The DKI mutation used to disrupt whole-body AMPK-glycogen binding in mice leads to simultaneous increases in serum insulin levels and adiposity, contributing to the progression of glucose intolerance characteristic of the early stages in the development of insulin resistance. This evidence concerns the gene INS and Insulin resistance.